Avanos Medical (AVNS) 10-Q2022 Q2 Quarterly report

Filed: 9 Aug 22, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accordion, agent, bank, Citibank, clarify, create, default, direct, discretion, dispose, event, extinguishment, feature, financing, grant, greatest, guarantee, guaranteed, hedging, indemnification, indirect, installment, lien, loan, merger, month, negotiated, notice, Notwithstanding, NYFRB, open, overnight, penalty, percent, permitted, premium, prime, priority, redeem, Restated, scheduled, simple, subfacility, suspended, thereunder, transfer, Unamortized, wholly, withheld

Removed: equal, excluding, freight, initiated, located, March, obsolescence, percentage, substance, unit

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated AVNS transcripts

AVNS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32(b)

Certification of Chief Financial Officer

Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code

I, Michael C. Greiner, Chief Financial Officer of Avanos Medical, Inc., certify that, to my knowledge:

(1)the Form 10-Q, filed with the Securities and Exchange Commission on August 9, 2022 (“accompanied report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the accompanied report fairly presents, in all material respects, the financial condition and results of operations of Avanos Medical, Inc.


Date: August 9, 2022						/s/ Michael C. Greiner
						Michael C. Greiner Chief Financial Officer